Much of what is known about the deleterious effects of tobacco use on health was learned from epidemiologic studies over the last half century. These studies establish unequivocally that tobacco use, particularly manufactured cigarette smoking, causes most cancers of the lung, oropharynx, larynx, and esophagus in the USA, and approximately one-third of all cancers of the pancreas, kidney, urinary bladder and uterine cervix. More recent evidence also implicates smoking with cancers of the stomach, liver and colorectum. While over half of the estimated 440 000 smoking-attributable deaths that occur annually in the USA involve non-malignant cardiovascular and respiratory conditions, smoking-attributable cancers are more recognized and feared. Geneticists increasingly study tobacco use as a model for environmental carcinogenicity. Tobacco-exposed populations provide opportunities to characterize the somatic mutations that give rise to specific cancers and to identify the inherited genetic traits that confer susceptibility or resistance. Studies to identify the genetic determinants of addiction may be particularly important. Future research to identify other susceptibility factors, such as genes that modify carcinogen metabolism or DNA repair, will need to be substantially larger and to quantify lifetime tobacco exposure with more precision than have past studies in order to distinguish gradations in risk due to exposure from those caused by genetic susceptibility. This review considers: (a) the epidemiology of tobacco use; (b) cancers presently classified as smoking-attributable by the US Surgeon General; (c) the magnitude of the epidemic of cancers and other diseases caused by tobacco use; (d) selected issues in the epidemiology of lung cancer; and (e) the interface of genetics and epidemiology in understanding, preventing, and treating tobacco-attributable disease.
Introduction
Geneticists and epidemiologists have traditionally concentrated on opposite sides of gene-environment interactions. For example, hundreds of epidemiologic studies have documented the relationship between tobacco use and over 20 diseases without the need or ability, historically, to examine the effect of inherited genetic traits on individual susceptibility. Similarly, medical geneticists have studied rare, high penetrance genes in affected families without consideration of environmental exposures. Recently, geneticists and molecular epidemiologists have begun studying tobacco as a model of environmental carcinogenesis. Of particular interest has been the identification of the somatic mutations caused by smoking or other forms of tobacco use that result in particular cancers, and the inherited genetic variation that may influence susceptibility or resistance to the addictive or carcinogenic properties of tobacco.
Epidemiologic (non-randomized) studies have been uniquely suited to examining the deleterious health effects of tobacco in human populations. Humans, unlike other mammals, use tobacco voluntarily. Whereas tobacco smoke is irritating and highly toxic to other species, humans develop physiological and psychological dependence that obligates continued exposure. Epidemiologic studies are better suited than clinical observations to surmount the long delay between the initiation of tobacco use and the diagnosis of, or death from, invasive cancer. Observational studies continue to be ethical and feasible, whereas randomized clinical trials are not. Many of the associations between tobacco use and specific disease conditions are sufficiently strong that they can be demonstrated by measuring average risk in exposed persons, without consideration of genetic susceptibility and despite imprecise quantification of lifetime tobacco exposure.
More recently, advances in molecular biology have allowed geneticists and molecular epidemiologists to characterize the mutations and epigenetic events that mediate the development of tobacco-attributable cancers. Clinical studies of smokers or of persons with cancers that are rare in the USA in the absence of tobacco use allow the construction of genetic progression models for tumors of the oropharynx, larynx, lung and esophagus (Westra and Sidransky, 1998) . Such models provide the basis for clinical tests to detect specific genetic alterations in tumor cells that can be used to diagnose cancer earlier, more accurately predict prognosis, and monitor tumor response to therapy (Sidransky, 1995) . Genetic changes in somatic cells may also provide molecular 'fingerprints' that indicate whether a particular individual's cancer was caused by a specific 'environmental' exposure, such as smoking.
Rapid advances in laboratory technology also provide new opportunities to study genetic susceptibility to tobacco and gene-environment interactions in large-scale population studies. Not all individuals are equally susceptible to carcinogenic exposures (Perera, 1996) . Inherited genes can, in principle, modify susceptibility across the entire spectrum of smoking initiation, addiction, carcinogen metabolism, host repair, and tumor suppression. Hereditary factors could, for instance, influence an individual's tendency to experiment with tobacco, to become dependent on its use, to activate, detoxify, or excrete absorbed carcinogens, to stop smoking, and/or to repair or eliminate genetic damage from smoking. Interactions of common, low penetrance genotypes with common environmental exposures such as tobacco may have a relatively small effect on individual risk of disease, but still contribute a substantial proportion of cases in the population. It is important, however, that geneticists and molecular epidemiologists who study tobacco appreciate the challenges posed by observational studies of such interactions, particularly in relation to exposure quantification and sample size.
This review considers the epidemiology of tobacco use and cancer with respect to issues that may be most relevant to geneticists who study smoking. We begin by identifying underlying patterns of tobacco use that have profoundly affected the occurrence of cancer and other diseases. We then discuss the history of the recognition of adverse health effects from smoking, the criteria that define causation, the conditions presently classified as smoking-attributable by the US Surgeon General, the magnitude of the epidemic, selected aspects concerning the epidemiology of lung cancer, and the interface of genetics and epidemiology in understanding, preventing and treating tobacco-attributable diseases.
Underlying patterns of tobacco use Over 1.2 billion people use tobacco worldwide (Corrao et al., 2000b) . Consumption of manufactured cigarettes continues to increase in many parts of Asia, Latin America and Eastern Europe, even as it decreases in wealthy countries (Corrao et al., 2000a) . Within the USA, historical changes in tobacco products and in patterns of usage over the last century have dramatically influenced the number of people smoking and the tissues exposed to the toxic and carcinogenic substances in tobacco.
Types of tobacco products
Most tobacco use in the early 1900s involved chewing tobacco, pipes, cigars, and snuff rather than cigarettes (Smith and Fiore, 1999) . Figure 1 shows the extraordinary increase in the consumption of manufactured cigarettes in the USA beginning after 1910 (Smith and Fiore, 1999; US Department of Agriculture, 2001) . By the mid-1940s, cigarettes had largely displaced other tobacco products. The commercial success of manufactured cigarettes occurred because of the convergence of several technological and social innovations, including the development of safe and portable matches, the creation of equipment to mass-produce and package cigarettes inexpensively, the introduction of massmedia campaigns to promote special brands, and the (Slade, 1993) .
A consequence of the shift from traditional tobacco products to manufactured cigarettes was a large increase in the epithelial surface area of the upper respiratory tract of smokers directly exposed to the carcinogens in tobacco. The use of snuff and other smokeless tobacco products caused localized contact of the lip and oral cavity with tobacco leaf or extracts dissolved in saliva. The alkaline smoke from cigars, pipes, and traditional roll-your-own cigarettes discouraged deep inhalation. As a consequence of their alkalinity, these products and smokeless tobacco released an un-ionized form of nicotine that could be absorbed through the oropharyngeal mucosa (Henningfield et al., 1993; Slade, 1993) . In contrast, the new strains of tobacco leaf and curing processes developed for manufactured cigarettes yielded a less alkaline smoke that had to be inhaled into the trachea and large bronchi to allow absorption of ionized nicotine (Henningfield et al., 1993; Slade, 1993) . The principal location of tobacco-attributable cancers consequently shifted from oropharyngeal and laryngeal tumors to cancers of the trachea, bronchus and lung.
Changes in the composition of tobacco smoke
Tobacco smoke is a heterogeneous mixture that contains approximately 4000 chemical compounds, including 40 different substances classified as carcinogenic to humans or animals (US Department of Health and Human Services, 1989) . Many of these carcinogens cause the same types of cancer in occupational or laboratory settings as occur in smokers. Constituents of cigarette smoke known to cause lung cancer include polycyclic aromatic hydrocarbons (PAH), N-nitrosamines, inorganic compounds (nickel, chromium, cadmium, polonium-210, arsenic, hydrazine) and certain organic compounds (1,3-butadiene, ethyl carbamate) (Hecht, 1999) . The organic chemical 2-napthylamine is a recognized carcinogen of the urinary bladder in occupational studies (Doll, 1998; Iarc, 1987) . Benzene causes myelogenous leukemia (Iarc, 1987) .
The extent to which changes in cigarette design have altered the composition and carcinogenicity of this complex mixture of chemicals has been difficult to measure in practice, because of compensatory changes in smoking behavior. Certain design changes in cigarettes, such as the introduction of blended tobacco in the 1950s, have increased the concentration of tobacco-specific nitrosamines. Other changes, such as the introduction of filter tip cigarettes, ventilation holes to dilute the smoke, and puffed tobacco have reduced the apparent delivery of 'tar', as measured by machine smoking, but led smokers to compensate by smoking more intensively and inhaling more deeply (Benowitz, 2001) . The actual exposure of smokers is influenced by puff volume, depth of inhalation, retention time in the lung, and number of puffs per cigarette, parameters that appear to have changed over time but are difficult to measure in large epidemiologic studies (Djordjevic et al., 2000) .
Rise and fall in per capita cigarette consumption Figure 2 shows the estimated trend in adult per capita cigarette consumption, here expressed as the number of cigarettes smoked per day rather than as pounds of tobacco. Per capita consumption increased over 80-fold in the USA from 1900 (an average of 54 cigarettes per year) to a peak in 1963 (4345 cigarettes per year) and then decreased to 2051 cigarettes per adult (518 years) per year in 2001 (US Department of Agriculture, 2001). Short-term fluctuations in consumption coincided with social, political, and economic events likely to influence either cigarette demand or availability. Most notable were the increases in consumption that occurred during and after USA involvement in the two World Wars, and the substantial decreases in consumption during the Great Depression and following the 1964 Surgeon General's report on Tobacco and Health (US Public Health Service, 1964) . A limitation of these data is that they do not indicate consumption patterns in relation to age, sex, or other characteristics. They do, however, indicate that cigarette consumption was not static, but highly dynamic, and responded quickly to external events.
Decline in the prevalence of cigarette smoking after 1965
In 1955, the first national survey of cigarette smoking in USA adults, age 18 years and older, reported that 56.9% of men and 28.4% of women were current smokers (Haenszel et al., 1956) . Smoking prevalence had been even higher in Britain between 1948 and 1952, where nearly 70% of men and over 40% of women aged 25 -59 years currently smoked cigarettes (Peto et al., 2000) . Following the 1964 US Surgeon General Report on Smoking and Health (US Public Health Service, 1964), the age-adjusted prevalence of cigarette smoking among USA males, age 518 years, decreased from 51.2% in 1965 to 25.2% in 1999 (Eberhardt et al., 2001) . The corresponding decrease in smoking prevalence among women over the same time period was from 33.7 to 21.6% (Eberhardt et al., 2001) .
Birth cohort patterns in smoking prevalence
Much of the dynamic increase in cigarette smoking occurred prior to the first national survey of smoking prevalence in 1955 (US Department of Agriculture, 2001) . However, the prevalence of cigarette smoking according to birth cohort and age has been reconstructed from information collected by the National Center for Health Statistics beginning in 1965 ( Figure  3 ) (Burns et al., 1997; Harris, 1983 Accompanying the birth cohort trends in the prevalence of smoking was a progressive shift towards earlier age of initiation among smokers across all birth cohorts of men from 1870 -79 to 1940 -49, and across cohorts of women born from 1870 -79 to at least 1950 -59 (Table 1) (Thun et al., 1997a) . The average age of initiation within each birth cohort is remarkably consistent in the four large studies included in Table 1 . These include the two American Cancer Society Cancer Prevention Studies I (CPS-I) and II (CPS-II) begun in 1959 and 1982 respectively (Thun et al., 1997a) . Also included are data from the National Health Interview Surveys conducted in 1987 -88 (Burns et al., 1997) and in 1998 (http://www.cdc.gov/nchs/nhis.htm).
Distinctive birth cohort patterns in smoking prevalence occur because tobacco dependence is usually established during critical periods of adolescence or young adulthood. Smoking is then sustained by addiction to nicotine and the behavioral aspects of tobacco use into older age ranges, where most cancers occur (Thun et al., 1997c) . Birth cohort patterns in the age of initiation reflect the impact of tobacco marketing and changing social norms. Overall, the birth cohort patterns reflect both the biological effects of tobacco dependence and the behavioral influence of social, economic, and political factors.
Adverse health effects from smoking

History
Sir Richard Doll, one of the first scientists to report an association between smoking and lung cancer, has reviewed the fascinating medical history of tobacco since its introduction into Europe from the New World in the 1400s (Doll, 1998) . In Europe, pipe smoking was advocated first as a medicinal practice and, by the late 1500s, for recreation. Attempts by James I to discourage tobacco use on moral and aesthetic grounds were unsuccessful. Pipe smoking spread from England to many European countries, later to be displaced by the use of snuff and cigars. Cigarettes were introduced into Britain in the late 1800s and became the predominant form of tobacco use after World War I. Doll notes that, in retrospect, medical evidence of the harm done by smoking has accumulated over at least 200 years, even though the evidence was not widely accepted until the mid-twentieth century (Doll, 1998) . Clinical reports as early as 1795 linked pipe smoking with carcinoma of the lip and tongue (Clemmesen, 1965; Sommering, 1795) . These were not taken very seriously, however, and were generally attributed to the heat of the clay pipe stem rather than to any intrinsic carcinogenicity of tobacco (Doll, 1998) . Results from the earliest attempts to induce skin cancer experimentally by applying tobacco 'tar' to laboratory animals were equivocal (Cooper et al., 1932; Leitch, 1928; Passey, 1929) . Tobacco tar produced notably fewer tumors than did similar applications of coal tar. Despite the demonstration by Roffo in the early 1930s that tobacco 'tar' could induce skin cancer in rabbits (Roffo, 1931) , the carcinogenicity of prolonged dermal exposure was not widely acknowledged until the publication of six additional confirmatory studies in the 1950s (Croninger et al., 1958; Engelbreth-Holm and Ahlmann, 1957; Guerin and Cuzin, 1957; Sugiura, 1956; Wynder et al., 1953 Wynder et al., , 1955 .
Two other factors that delayed recognition of the harmful health effects of tobacco were the widespread use of tobacco by doctors and scientists, and the delayed application of systematic epidemiologic methods to chronic diseases such as cancer and cardiovascular disease (Doll, 1998) . Smoking was entrenched among male doctors and scientists by the mid-twentieth century. Furthermore, epidemiologic research methods had been used mainly to study infectious diseases. Clinical studies published before 1950 were case series or ecological studies that did not include a comparison group and could not systematically compare disease occurrence in smokers with that in people who had never used tobacco (Doll, 1998) .
A critical turning point in the medical evidence regarding smoking and cancer was the publication, in 1950, of five case -control studies that showed a clear association between smoking and lung cancer (Doll and Hill, 1950; Levin et al., 1950 ; Mills and Porter, Schrek et al., 1950; Wynder and Graham, 1950) . These led quickly to several large cohort studies that subsequently confirmed the association of cigarette smoking with not only lung cancer, but also with coronary heart disease and death from all causes Hill, 1954, 1956; Hammond, 1966; Hammond and Horn, 1958; Kahn, 1966) .
Criteria defining causation
The qualitative judgment that smoking causes a particular disease signifies that, in the absence of tobacco exposure, some fraction of cases or deaths would not occur or would occur at a later age (Rothman and Greenland, 1998; US Public Health Service, 1964) . It does not require that smoking be necessary or sufficient for the disease to occur. For example, tobacco use is an established cause of myocardial infarction, even though heart attacks can occur in the absence of smoking. Whereas many infectious diseases are named after the microorganisms that cause them, chronic diseases are multifactorial in etiology. An exposure need only influence the probability or timing of disease onset to be considered causal (Doll, 1998) .
Many independent scientific consensus groups have reviewed the epidemiologic and other evidence pertaining to tobacco use. Two organizations, the International Agency for Research on Cancer (IARC, 1986 ) and the US Surgeon General, have periodically designated conditions that are considered causally related to tobacco (US Department of Health and Human Services, 1989) . The criteria used to make this determination, often attributed to Sir Austin Bradford Hill, take into account the consistency, strength, temporal relationship, coherence, and specificity of the relationship (Hill, 1965) . Smoking is considered to cause a given disease if incidence or death rates are consistently increased in exposed persons across several large, well-conducted studies, if risk increases with the intensity and/or duration of continued smoking, and decreases (or diverges from the risk of continuing smokers) with cessation of smoking, and if the relationship is biologically plausible.
The fact that smokers have increased risk of many different diseases was initially counted as evidence against the relationships being causal (Berkson, 1955 (Berkson, , 1958 , since specificity was one of the criteria proposed by Sir Austin Bradford Hill as evidence of causation (Hill, 1965) . Many tissues in the body are exposed to toxic and carcinogenic substances from tobacco use, however. Systemic exposure occurs from compounds absorbed into the bloodstream. Localized exposure involves direct contact of the lip, tongue, and gums with tobacco leaf. Extracts of tobacco dissolved in saliva reach tissues of the oropharynx, larynx, esophagus, stomach, and intestinal tract. Compounds excreted in urine cause transient exposure of the kidneys and sustained exposure of the urinary bladder.
Until recently the tobacco industry disputed the evidence that tobacco use caused cancer or heart disease, contending that statistical associations do not constitute 'proof' (Glantz et al., 1996) . While true as an abstract principle (US Public Health Service, 1964), the industry's argument did not acknowledge the extent of the evidence from many different studies of varying design in different settings, the empirical nature of all medical research, and the standard required for 'proof' of toxicity from a commercial product. In reality, there has been no serious scientific controversy about whether smoking causes any of these conditions, except possibly cervical cancer, for several decades. The official stance of the tobacco industry has long represented a legal and political strategy rather than a manifestation of any genuine scientific debate (Glantz et al., 1996) . Service, 1964) . Other cancers, cardiovascular and respiratory diseases caused by active smoking and lung cancer and coronary heart disease resulting from second-hand smoke were added to the list as additional scientific evidence accumulated.
Diseases presently considered smoking-attributable
The nature and extent of the scientific evidence varies for different conditions and for different tobacco products, and has evolved and expanded over time. Associations that were judged to be causal in 1964 included cancers of the trachea -bronchus -lung, larynx, and chronic bronchitis in cigarette smokers, and lip cancer in pipe smokers (US Public Health Service, 1964) . For each of these conditions the relative risk estimates exceeded five among male current smokers, compared to lifelong non-smokers, in early cohort studies in the USA (Best et al., 1961; Dorn, 1959; Hammond and Horn, 1958; US Public Health Service, 1964) and UK Hill, 1956, 1964) . The relative risk of lung cancer in current cigarette smokers has subsequently increased from 11.9 to 23.2 in men and from 2.7 to 12.8 in women in two sequential American Cancer Society (ACS) cohorts (Thun et al., 1997a) . Additional histologic subtypes of certain cancers have become associated with smoking following changes in cigarette design and resultant inhalation patterns, and the changing prevalence of cofactors that affect risk. For example, in studies conducted through the 1960s cigarette smoking was strongly associated with squamous and small cell cancers of the lung (Doll et al., 1957; Kreyberg, 1962) and with squamous carcinoma of the esophagus (Auerbach et al., 1965) , but not with adenocarcinoma of the lung or esophagus. This has changed in the decades following the introduction of blended tobacco and filter-tip cigarettes. Cigarette smoking is now clearly associated with all histologic types of lung cancer (Thun et al., 1997c; Wu-Williams and Samet, 1994) , and with adenocarcinoma of the distal esophagus Lagergren et al., 2000) .
Magnitude of the epidemic of diseases caused by tobacco use
Tobacco use causes such a large disease burden from so many different conditions that the strategy of identifying genetically susceptible individuals on whom to focus tobacco control efforts is likely to be ineffective. Prolonged cigarette smoking is estimated to cause premature death in one of every two smokers (Peto et al., 1992) . In the USA, where manufactured cigarettes have been used extensively since the 1920s, cigarette smoking alone causes approximately 440 000 deaths each year (Table 2) (CDC, 2002) . This corresponds to approximately one of every five deaths (Mcginnis and Foege, 1993) , 30% (or approximately one of every three) of cancer deaths (Doll and Peto, 1981) , and an estimated $75.5 billion in personal health care costs (CDC, 2002) . Although cigarette smoking still causes almost as many deaths each year in the USA from cardiovascular conditions (nearly 149 000) as from cancer (approximately 156 000) (CDC, 2002), the cancers caused by smoking are more recognized and feared (Ford, 1994) . Tobacco is projected to become the single most important and preventable cause of disease in the world by the 2020s (Murray and Lopez, 1997) , as it is now in North America, Western Europe, and in other industrialized countries (Peto et al., 1992) .
Although the Surgeon General's estimates of smoking-attributable deaths (CDC, 2002) help to communicate the approximate magnitude of the epidemic caused by cigarette smoking, they are not intended to be a complete or precise inventory of all of the health effects of tobacco use. The estimates of attributable-risk in Table 2 do not consider tobacco products other than cigarettes, for example, and are limited to conditions that result in death. The disease of nicotine addiction is not included, even though this is reportedly the single most common psychiatric diagnosis in the USA (Bergen and Caporaso, 1999) and underlies most of the other detrimental effects of smoking. Other conditions that are not yet included in attributable risk estimates, but for which considerable evidence has now accumulated, are cancers of the colon and rectum, (Giovanucci, 2001 ) stomach, (Tredaniel et al., 1997) liver, (Doll, 1996) myeloid leukemia, (Doll, 1996) fatal (but not incident) prostate cancer (Hickey et al., 2001 ) and tuberculosis. For Table 2 , tobacco use or nicotine is inversely associated with risk. These include Parkinson's disease, ulcerative colitis, allergic alveolitis, and fibroids and cancer of the uterine corpus (Baron, 1996; Doll, 1998) . With the exception of deaths from prostate cancer, the inclusion of these conditions would result in only a small proportionate increase in the number of deaths already attributed to smoking in the USA. However, the designation of stomach cancer and tuberculosis as smoking-attributable diseases would have a large impact in countries such as China and India, where these conditions are common. Both the US Surgeon General and the International Agency for Research on Cancer (IARC) are currently reevaluating whether other conditions should be added to or removed from the list. As indicated above, the concept of attributable-risk signifies that in the absence of tobacco exposure, some fraction of cases either would not occur or would occur at a later time. It does not mean that tobacco is the only factor responsible for disease. For example, approximately 90% of lung cancer deaths in men could be prevented by the avoidance of cigarette smoking, even though some fraction of the lung cancers result from interactions between smoking and other exposures such as asbestos or radon gas. Abstinence from tobacco would also prevent many cancers of the oropharynx, larynx, and squamous cell carcinomas of the esophagus in the USA, even though much of the risk occurs because of combined exposure to tobacco and alcohol. Figure 4 illustrates the increase in the odds ratio of oropharyngeal cancer associated with various combinations of increasing tobacco and alcohol exposure. The relative risk is highest among long-term smokers who consume 15 or more drinks per week. A consequence of the multifactorial etiology of cancer, and of the fact that many cancers result from combined exposure to more than one factor, is that the sum of the attributable fractions calculated in this way generally exceeds 100%. The overlap of attributablerisk estimates is likely to be further complicated in the near future by the discovery of numerous geneenvironment and gene -gene interactions.
Epidemiology of lung cancer and smoking
Lung cancer comprises less than 30% of the deaths attributable to smoking (CDC, 2002 ), yet it illustrates certain features of the relationship between tobacco and cancer more clearly than other disease endpoints. We address: (a) temporal trends in age-adjusted incidence and death rates from lung cancer in the general population; (b) the relationship between birth cohort trends in lung cancer and historical patterns of cigarette smoking; (c) the relationship of smoking and age to lung cancer risk; (d) estimates of the lifetime probability that a smoker will develop lung cancer; (e) changes in lung cancer risk that occur after smoking cessation; and (f) current controversies about lung cancer susceptibility in relation to gender, race and ethnicity.
Lung cancer rates in the general population
The age-adjusted death rate from lung cancer had already begun to increase among men in 1930, when mortality statistics first became available for most of the nation, whereas the increase among women began around 1960 ( Figure 5 ). Among men, the death rate continued to increase almost 20-fold from 1930 to its peak of 75.2 per 100 000 in 1990 (Ries et al., 2001) . This increase represents the largest absolute and proportionate change in any cancer over the same time period. A more than 25-year delay occurred after the downturn in per capita cigarette consumption in 1963 and the decline in smoking prevalence evident among men in 1965 (Eberhardt et al., 2001 ) before the initial decrease in the age-adjusted lung cancer death rate after 1990. Figure 5 also shows the temporal trend in age-adjusted lung cancer incidence rates within the nine National Cancer Institute SEER registries from 1973 (when these Registries began) to 1999 (Ries et al., 2001) .
So distinctive is the temporal relationship between cigarette smoking and lung cancer mortality that national lung cancer statistics can be used to estimate the stage of the tobacco epidemic and approximate number of deaths attributable to smoking within a particular country, despite the lack of national data on smoking prevalence (Peto et al., 1992) . In most countries, the uptake of cigarette smoking and subsequent increase in lung cancer begins earlier in men than women. At least in Western countries, smoking behavior and later lung cancer occurrence have become progressively more similar between men and women over time.
Birth cohort trends in lung cancer death rates
Underlying the age-adjusted lung cancer death rate is a more complex pattern of age-specific death rates that vary across birth cohort and calendar intervals, closely paralleling historical trends in cigarette smoking. Figures 6 and 7 depict the temporal trends in agespecific lung cancer death rates in white and non-white men and women respectively from 1930 to 1996. Within each age group, the lung cancer death rate first increases and later decreases. The downturn in the lung cancer death rate begins earlier at younger than at older ages. The maximum lung cancer death rate within each age group occurs in men born during the 1920s and women born during the 1930s. The absolute changes in the rate are larger in men than women, and at older ages (455 years) than in the young, yet birth cohort patterns are evident across all ages and both sexes. These patterns mirror generational trends in cigarette smoking (Figure 3) , and illustrate how birth cohort patterns of tobacco use affect lung cancer risk throughout adult life. The relevance of birth cohort to genetic studies of tobacco is discussed below.
Age and smoking-specific lung cancer death rates
Although the relationship between cigarette smoking and lung cancer is evident from vital statistics on the general population, without stratifying on individual smoking behavior, it is best seen in studies that can separate smokers from nonsmokers. Particularly informative are large cohort studies that provide estimates of absolute as well as relative risk of lung cancer and other endpoints in relation to smoking. Figure 8 shows the relationship of lung cancer death rates to age and smoking in the ACS cohort Cancer Prevention Study II (CPS-II) from 1982 to 1988. In this figure, risk is expressed as an annual death rate (per 100 000). The lung cancer death rate increases exponentially with age in both current-and never-smokers. The absolute rates are 20 -25 times higher among male smokers than never-smokers across most age groups, and 10 -12 times higher in female smokers than never-smokers. The relationship appears linear across most age groups when both age and the lung cancer death rate are plotted on a log scale, as noted previously in the British Doctors' (Doll and Peto, 1978; Pike and Doll, 1965) and US Veterans' (IARC, 1986) studies. The relationship is sub-linear in the oldest smokers (men and women aged 585 years), perhaps reflecting the combined effect of lower lifetime smoking in the oldest birth cohort and less complete ascertainment of lung cancer as a cause of death in the elderly.
Epidemiologic studies do not directly address the underlying mechanisms of carcinogenesis, yet some researchers have noted that the exponential increase in lung cancer that occurs with age is consistent with the proposed multistage events in carcinogenesis (Doll and Peto, 1978; Gaffney and Altshuler, 1988; Moolgavkar and Luebeck, 1990; Peto et al., 1985 ). An exponential increase in incidence with age could reflect the clonal proliferation of populations of cells in which previous mutations inhibit tumor suppression genes, apoptosis and/or DNA repair. The 'latency' or time required for such events to accumulate within a single cell may vary but is considerably longer than appreciated. For example, in CPS-II, the median delay between the initiation of smoking and death from lung cancer in the smoker is 50 years. Large variations in the strength of the association between cigarette smoking and lung and other cancers often occur in studies from different time periods and geographic areas, reflecting different stages in the evolution of the epidemic.
Lifetime probability that a smoker will develop lung cancer
Large cohort studies reveal that the lifetime risk that a smoker will develop lung cancer has increased over time in the USA and is conditional on lifetime smoking practices and competing causes of death. The frequently quoted axiom that 'only 10% of cigarette smokers develop lung cancer' (Mabry et al., 1998) underestimates the current lifetime probability. Mattson et al. (1987) estimated the probability that a male smoker, age 35 years, would develop lung cancer by age 85 years, given continued smoking. Based on analyses by Kahn (1966) of over 293 000 US Veterans followed from 1954 to 1962 (Kahn, 1966) , Mattson et al. (1987) estimated that 9.3% of men who smoked 525 cigarettes per day at age 35 would develop lung cancer by age 85, and 17.9% of those who smoked 525 cigarettes per day. From this has come the estimate that 'only 10%' of smokers develop lung cancer, and the inference that genetic susceptibility influences lung cancer risk (Mabry et al., 1998; Spivack et al., 1997) .
More recent cohort studies indicate that the lifetime probability of a continuing smoker developing lung cancer has increased slightly over time. Figure 9 depicts the cumulative probability of death from lung cancer in male and female smokers and lifelong nonsmokers at various ages, based on data from Cancer Prevention Study II during follow-up from 1982 -88. It shows that the cumulative probability, not conditioned on surviving other causes of death, reaches 14.6 and 8.3% in male and female smokers, age 585 years, and is 1.1 and 0.9% at this age among male and female lifelong non-smokers. If the impact of competing causes of death were excluded from the calculation, the lifetime probabilities would be 24.1 and 11.0% in male and female smokers respectively, and 1.6 and 1.1% in men and women never smokers. The latter estimates are probably more relevant for estimating the fraction of genetically susceptible persons in the population than are the unconditional percentages, since they are independent of other causes of death. These estimates reflect only the effect of smoking on lifetime probability of death from lung cancer. The estimates would be much higher if they considered all of the adverse effects of smoking.
Trends in lung cancer risk after smoking cessation
The fact that the risk of lung and other cancers attributed to smoking becomes lower in people who stop smoking than in those who continue is an important piece of the evidence for causation. It strongly indicates that continuing exposure affects even the late stages of carcinogenesis. Figure 10 depicts the relationship between age and the cumulative probability of death from lung cancer according to smoking status in CPS-II from 1984 -91. It is based on nine rather than 6 years of follow-up to increase the statistical precision of the estimates, and excludes the first two years of follow-up (1982 -83) to avoid bias from smoking cessation due to tobacco-attributable disease. In both men and women, the age-related increase in lung cancer risk is lowest in people who have never smoked, intermediate in those who have quit at various ages, and highest in those who continue smoking. Among former smokers, the age-related increase is smaller the earlier the age of quitting. As seen in Figure 10 , the cumulative probability of death from lung cancer continues to increase with age, even in persons who have never smoked or have stopped smoking, but the increase is substantially slower than in persons who continue to smoke. Studies that measure relative rather than absolute risk find that the relative risk of lung cancer approaches unity with time since cessation in former smokers, compared with those who have never smoked (US Department of Health and Human Services, 1990) . The relative risk estimates fall below unity with time since cessation in former smokers compared to continuing smokers. If cardiovascular diseases are considered as well as cancer, smokers who stop smoking by age 50 avoid most of the excess risk caused by smoking (Peto et al., 2000) . 
Controversies regarding lung cancer susceptibility by sex and race
Three current controversies concerning genetic susceptibility to lung cancer illustrate the difficulty of distinguishing variations in lifetime tobacco exposure from variations in genetic susceptibility. One involves the idea that women may be more susceptible to lung cancer than men with equivalent exposure to smoking (Zang and Wynder, 1996) . Others concern whether African American men who smoke are more susceptible than Caucasian men, and whether the latter are more susceptible than Japanese or Chinese men with comparable smoking habits. Although the interpretation of the putative sex and racial differences is complicated by semantic and methodological problems (Perneger, 2001; Thun, 1998; Wu-Williams and Samet, 1994) , a number of genetic and molecular epidemiologic studies have proposed mechanistic explanations for the differences. The epidemiologic evidence is discussed below.
Lung cancer risk in women versus men
At least ten case -control studies have reported that women who smoke have a higher relative risk of developing lung cancer from smoking than do male smokers (Brownson et al., 1992; Cohn et al., 1996; Harris et al., 1993; Lubin and Blot, 1984; Mcduffie et al., 1991; Osann et al., 1993; Prescott et al., 1998; Risch et al., 1993; Wynder, 1992, 1996) . Other studies have reported a similar gender difference for cancers of the urinary bladder (Castelao et al., 2001) and esophagus Gammon et al., 1997) . The hypothesis that women may be biologically more susceptible than men to develop cancer from an equivalent amount of smoking (King and Brunetta, 1999) has stimulated molecular studies to identify the genetic or biological basis for the putative sex difference (Ryberg et al., 1994; Shriver et al., 2000) . There is currently no good evidence that women are more susceptible to develop lung or other cancers from smoking than men, however, and there is much evidence that this is not the case. Women have similar or lower death rates from lung cancer than do men in large cohort studies such as CPS-II within equivalent strata of age and smoking (Table 3) (Thun et al., 2000) . Perneger (2001) has noted that all of the studies that postulate greater risk in women than men are casecontrol studies that estimate relative, but not absolute, risk. Publications from several of these case -control studies have used the terms 'risk' and 'relative risk' interchangeably (Risch et al., 1993; Wynder, 1992, 1996; Castelao et al., 2001) . Women have considerably lower background absolute risk of certain cancers than men in the absence of tobacco use, and relative risk estimates are typically higher when absolute background risk is low. Even the relative risk estimates for lung cancer associated with smoking are lower in women than in men at equivalent levels of smoking in CPS-II (Thun et al., 1997b) . Among other factors, women with lung cancer may report their smoking history differently in case -control studies than do men. Furthermore, the incidence and mortality rates from lung cancer are converging among young women and men in SEER registry areas and USA mortality data, consistent with the convergence in smoking patterns between the sexes (Jemal et al., submitted). In summary, there is currently no epidemiologic support for the idea that women are more susceptible to develop lung cancer than men. Biochemical, genetic, and mechanistic studies to explore this hypothesis seem unwarranted.
Lung cancer risk in African Americans versus Caucasians
The issue of genetic susceptibility is more complicated when comparing lung cancer risk in African Americans to that of Caucasians, since the difference in incidence and death rates is limited to men (Ries et al., 2001 ). Compared to white men, black men have higher incidence and death rates from lung cancer, younger age at diagnosis and shorter survival (Stewart, 2001) . Furthermore, the racial and ethnic differences in smoking vary considerably depending on the parameter being measured. Black men and women begin smoking at a later age than whites and consistently report smoking fewer cigarettes per day (Novotny et al., 1988) . However, smoking prevalence has been higher in black than white men since 1950 (Figure 3 ) (Burns et al., 1997) and the brands preferred by black smokers are more likely to be mentholated and to have higher machine-measured levels of nicotine and tar (King and Brunetta, 1999) . Black smokers have higher blood levels of cotinine, the main metabolite of nicotine, than do whites smoking a similar number of cigarettes per day (King and Brunetta, 1999) . Several genetic studies report that black smokers have a distinctive polymorphism of the CYP1A1 gene associated with adenocarcinoma of the lung compared to white smokers Crofts et al., 1993; London et al., 1999; Shields et al., 1993; Taioli et al., 1998) . Consequently, the carcinogenic or mutagenic agents in tobacco smoke may be metabolized and excreted at different rates in blacks than in whites (King and Brunetta, 1999; Perez-Stable et al., 1998; Richie et al., 1997) .
Lung cancer risk in Asians versus Caucasians
Comparisons of lung cancer risk in Caucasians with that in Chinese and Japanese populations residing in Asia or in the West are also perplexing. Lung cancer rates are high among non-smoking women in certain areas of China due to indoor cooking with poorly vented coal-fueled stoves (Fraumeni and Mason, 1974; Law et al., 1976) . However, the relative risk for lung cancer associated with cigarette smoking is lower among women in Japan (Stellman et al., 2001) and China (Liu et al., 1998; Niu et al., 1998; Yuan et al., 1996) than in the West. Lung cancer death rates among male smokers are also lower in large cohort studies in Japan (Wakai et al., 2001) than in the USA (Thun et al., 1997a) . Peto and others attribute this difference to the more recent initiation of serious smoking, since the main increase in cigarette smoking occurred 40 years later in China than in the USA (Liu et al., 1998; Niu et al., 1998) . However, the relative risk of lung cancer ranges between 3 and 5 among middle-aged women and men in the largely (95%) Chinese population of Hong Kong, where cigarette smoking prevalence reached its peak about 20 years earlier than in mainland China (Lam et al., 2001) . There is some evidence that differences in nicotine metabolism may contribute to differences in the intensity of smoking between Caucasians and Orientals. Benowitz et al. (2002) have reported slower clearance and reduced intake of nicotine from cigarette smoking among Chinese-Americans than whites, that they postulate may cause Asian smokers to smoke fewer cigarettes per day. This issue has not been resolved.
Interface of genetics and epidemiology in tobacco research
Models of genetic progression
One area in which genetic research contributes to the scientific understanding of tobacco and cancer is through the construction of genetic progression models of carcinogenesis. These identify the molecular events that underlie the progressive phenotypic abnormalities caused by tobacco use. For example, it has long been known that tobacco exposure causes leukoplakia and erythroplasia in the oropharynx (Silverman, 1998) . The histologic appearance of these lesions becomes progressively more dysplastic with continuing exposure, but often recovers after cessation of tobacco use (Martin et al., 1999) . Analogous abnormalities have been observed in autopsy studies of smokers in bronchial epithelium (Auerbach et al., 1961 (Auerbach et al., , 1962 (Auerbach et al., , 1964 (Auerbach et al., , 1979 , larynx (Auerbach et al., 1970) , esophagus (Auerbach et al., 1965) and pancreas (Auerbach and Garfinkel, 1986) . Molecular studies have now characterized many of the genetic events that underlie the transition from normal epithelium to hyperplasia, squamous metaplasia, dysplasia, carcinoma in situ, and to invasive carcinoma in the lung (Minna et al., 2002) and other aerodigestive tract tissues (Califano et al., 1996) . Mutations that activate oncogenes or inactivate tumor suppressor gene accumulate during the development of cancers of the oropharynx (Guo et al., 2001) , larynx (Califano et al., 2000) , lung (Hecht, 2000) , and esophagus (Califano et al., 1999; Montesano et al., 1997) . For example, mutations that correlate with malignant progression in oropharyngeal neoplasia include inactivation of p53 and chromosomal polysomy (Lee et al., 2000; Mao et al., 1996) . Clonal proliferation results in widespread 'field cancerization' and increased risk of recurrent or second cancers (Westra and Sidransky, 1998) .
While it is not necessary to determine the underlying molecular events to establish causality, advances in understanding the biology of carcinogenesis may soon have clinical application. Westra and Sidransky (1998) have demonstrated that clones of genetically damaged cells can extend beyond the microscopically visible premalignant or malignant lesions in head and neck cancer. Molecular markers can potentially be used to identify genetically abnormal but phenotypically normal cells at the margins of surgically resected head and neck cancers to reduce tumor recurrence (Westra and Sidransky, 1998) , predict prognosis, and guide treatment (Guo et al., 2001) . Construction of genetic progression models does not necessarily require large population studies. Serial examinations of a few heavily exposed individuals have established the importance of clonal proliferation. Cancers are sufficiently heterogeneous, however, that genetic characterization of the full spectrum of tumors that occur in clinical practice will require a broader, more systematic approach to sampling.
It may also become possible to identify combinations of molecular markers that provide a distinctive 'fingerprint' and identify the cause(s) of cancer in an individual patient, not merely increased or decreased average risk in a population. Denissenko et al. (1996) have identified concentrations of DNA adducts and mutational hotspots within the p53 gene in tumors from smokers. Adducts detected at specific codons of the p53 gene have been reported to contain benzo(a)-pyrene, other polycyclic aromatic hydrocarbon diol epoxides, and activated carcinogens from the metabolism of tobacco smoke.
Genetic determinants of addiction
A second area where genetic research could make a major contribution to tobacco control is by identifying genetic and biological determinants of addiction. Regular use of tobacco and other nicotine delivery devices produces drug dependence in exactly the same sense that regular ingestion of heroin, cocaine, and alcohol produce dependence (Henningfield et al., 1993) . Studies involving twins strongly implicate genetic factors in relation to smoking initiation and persistence (Bergen and Caporaso, 1999; Heath et al., 1995) . Recent linkage studies indicate regions of the genome in which loci affecting nicotine dependence and ever smoking may be found (Bergen and Caporaso, 1999; Straub et al., 1999) . Although smokers vary in the severity of their addiction, dependence on nicotine and on the behavioral patterns of smoking is what keeps people smoking (US Department of Health and Human Services, 1988) . Surveys show that 70% of smokers want to quit smoking completely, and that 46% try to quit each year (CDC, 1997) . Therefore, studies exploring the biology of addiction, and genetic polymorphisms that influence dopamine and serotonin function could help in the development of more effective drugs to prevent or treat tobacco dependence.
Genes that affect carcinogen metabolism
Much of the research on genetic variants that modify susceptibility to tobacco carcinogens concerns three superfamilies of drug-metabolizing enzymes (Lang and Pelkonen, 1999) . Cytochrome P450 (CYP) enzymes catalyze Phase I oxidation reactions that detoxify procarcinogens in tobacco smoke such as polycyclic aromatic hydrocarbons (Lang and Pelkonen, 1999) , arylamines, and heterocyclic amines (Landi et al., 1999; Lang and Pelkonen, 1999; Strong and Amos, 1996) but also form intermediate products that are genotoxic or carcinogenic (Bartsch et al., 2000) . Glutathione Stransferase (GST) enzymes detoxify and eliminate reactive electrophilic intermediates, such as those formed by phase 1 enzymes (Strange and Fryer, 1999) . N-acetyltransferases (NAT) acetylate aromatic and heterocyclic amines and hydrazines (Lang and Pelkonen, 1999) . Substrates for NAT include arylamines in cigarette smoke (2-napthylamine and 4-aminobiphenyl) and related chemicals used in the rubber and dye industries.
Genes that affect DNA repair
More recently, molecular epidemiologic studies have begun to examine genes that influence DNA repair as well as carcinogen metabolism in relation to susceptibility to tobacco. Smokers with diminished ability to excise or repair somatic mutations before cell division may be more susceptible to develop tobacco-attributable cancers. This has been studied in relation to cancer of the lung (Ratnasinghe et al., 2001 ) and urinary bladder (Stern et al., 2001) . However, studies of DNA repair confront many of the same challenges that complicate molecular epidemiologic studies of carcinogen metabolism, as discussed below.
Rationale for studying genetic susceptibility
There are both scientific and clinical reasons to identify gene-environment interactions that may influence individual susceptibility to carcinogens in tobacco smoke or to faulty DNA repair. Valid markers of genetic susceptibility factors may help scientific efforts to clarify etiologic relationships that are presently confusing or inconsistent. For example, available data are conflicting as to whether post-menopausal women with the slow phenotype of N-acetyltransferase are genetically more susceptible to develop breast cancer from tobacco use than other women (Ambrosone et al., 1996) , or whether nonsmokers who are homozygous for the GTSM1 null allele have particularly high risk of developing lung cancer from environmental tobacco smoke (ETS) (Bennett et al., 1999; Weinberg and Sandler, 1999) . It may be clinically valuable to identify subcategories of addicted smokers and to individualize smoking cessation treatment, or to identify high-risk persons for enrolment in chemoprevention trials or special cancer screening programs that are not appropriate for the general population (Bartsch et al., 2000) . In contrast, genetic screening and counseling will probably not be effective in deterring smoking initiation among adolescents, since teenagers who are most likely to smoke may be the least likely to participate in or accept genetic counseling. Genetic screening is also unlikely to reduce the cost of smoking cessation programs, since approximately 50% of longterm smokers die prematurely because of their tobacco use (Peto et al., 1994) , and the expense of genetic testing will outweigh any savings from narrowing the population to be treated. Nevertheless, personalized genetic counseling may help to guide the selection of pharmacological and behavioral treatments for individual smokers, and may motivate some individuals to quit.
Strategies to improve studies of gene-environment interactions
Several reviews have proposed strategies to improve the design and interpretation of future molecular epidemiologic studies of gene-environment interactions, specifically as these concern tobacco exposure (Bartsch et al., 2000; Brockton et al., 2000; Cardon and Bell, 2001; Garte, 2001; Geisler and Olshan, 2001; Green et al., 2000; Houlston, 1999) . All of these reviews note that the results from published studies have been conflicting and difficult to replicate. Limitations of many of the published studies include limited statistical power, over-emphasis of unexpected but statistically significant associations observed in subgroup analyses, inadequate emphasis on a priori hypotheses, a focus on one or several genes in isolation rather than genetic pathways, and imprecise characterization of lifetime exposure to tobacco.
Sample size
Massive studies are needed to examine interactions between an environmental factor such as smoking and genetic polymorphisms that are common in the general population but have low penetrance. For example, a minimum of one thousand cases is needed to assess a two-way gene environment interaction in a casecontrol analysis with 80% power, given a 10% frequency of both the genetic polymorphism and the environmental factor, a main effect relative risk (RR) of 1.3 for both the genetic and environmental exposure, an expected RR associated with interaction =2.0, and an alpha level of 0.05 (Garcia-Closas and Lubin, 1999; Geisler and Olshan, 2001; Green et al., 2000) . Much larger sample sizes are needed to examine higher order interactions, less common genetic variants, and weaker associations. Although molecular epidemiologists increasingly recognize the need for larger studies, the costs of establishing studies of sufficient size and of systematically examining metabolic pathways are formidable compared to the costs of studying rare, high penetrance, single gene disorders in high-risk families. It may be more feasible to explore geneenvironment interactions by extensive genotyping within consortiums of large existing studies than for individual institutions to work separately.
Study design and interpretation
Spurious associations can be observed in observational studies because of faulty design, analysis, or interpretation. The methods by which a study population is selected can profoundly influence inferences that can be drawn from the results. For instance, studies of women drawn from families at high risk of breast cancer initially suggested that the penetrance of BRCA1 and BRCA2 was substantially higher than proved to be the case in the general population (Hopper et al., 1999; Malone et al., 1998; Newman et al., 1998; Struewing et al., 1997) . Control for confounding is always essential, especially when studying small to moderate associations such as are expected to influence the majority of cases with complex diseases such as cancer. Future studies of gene expression may be susceptible to confounding by age and comorbidity, tumor characteristics, and treatment. For example, gene expression in casecontrol studies may be differentially influenced by the disease or treatment of cases. Spurious associations can also be introduced by chance when unexpected but statistically significant associations observed in small subgroups are overemphasized (Green et al., 2000) .
Categorization of lifetime tobacco exposure
It is more difficult to study tobacco exposure as a model of gene -environment interactions than is commonly realized, because gradations in the duration and intensity of exposure strongly influence risk, yet lifetime exposure is imprecisely quantified. Most molecular epidemiologic studies classify tobacco exposure crudely as 'ever' versus 'never' or according to pack years of smoking. The former does not consider the important effects of cessation on the risk of tobacco-attributable cancers. The variable pack-years equates the intensity (number of cigarettes or packs per day) and duration (years) of smoking with respect to cancer risk. However, in the British Doctors' Study, lung cancer risk has been shown to increase with the fourth or fifth power of years of smoking but with the second power of cigarettes smoked per day (Doll and Peto, 1978) . Future studies will need to characterize lifetime tobacco exposure more precisely in order to distinguish gradations in risk attributable to genetic susceptibility from those due to gradations in exposure.
Conclusions
Epidemiologic studies over the last half-century have demonstrated the immense burden of disease caused by tobacco use. Population studies reveal the scope of the global pandemic caused by manufactured cigarettes, its temporal progression within and across countries, and the remarkable number of disease it causes. All of the major 'environmental' factors that promote tobacco use (economic, social, and political), are highly modifiable. The wealthiest countries of the world have made substantial progress in reducing tobacco use at the population level, whereas the opposite is true in many economically developing countries.
Despite the overwhelming importance of environmental factors on tobacco use, both 'nature' and 'nurture' contribute to the likelihood that that an individual will experiment with tobacco, become addicted to its use, and develop cancer or other disease because of it. Recent advances in molecular biology provide unprecedented opportunities to understand the genetic determinants of tobacco dependence, the interaction between environmental and host factors in carcinogenesis, and the prognosis of specific tumors. Two major challenges are to integrate genetic research into population studies of sufficient size to study complex diseases such as cancer and to enhance rather than displace the continuing efforts on primary prevention.
